Opinion|Videos|January 27, 2026
Real‑World “Time Toxicity” and Patient Impact: Lessons from ASH 2025 for Epcoritamab in Follicular Lymphoma
A recent ASH study highlights the impact of CAR T and bispecific therapies on patient time commitment and quality of life in treatment decisions.
Advertisement
A recent real‑world analysis presented at American Society of Hematology Annual Meeting (ASH 2025) examined “time toxicity” — the burden of frequent healthcare visits and therapy‑related appointments — in patients treated with Epcoritamab. The study compared fixed‑duration regimens (such as for some bispecific antibodies) to continuous, treat‑to‑progression approaches, such as CAR-T therapies.
Advertisement
Related to this article
SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.
The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.
Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.
Cleveland roundtable panelists across 4 disease states name access, not evidence, as the shared barrier to care.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Alice Hall-Partyka, JD, a partner at Crowell & Moring explains the lawsuits challenging CMS' Medicaid rule on pediatric gender care and its legal weak points.
Siva Mohan, MD, explains how drug costs drive silent nonadherence, PA burden, and biosimilar hesitancy, and what payers can do about it.
Proinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.
Advertisement
Advertisement